Triptorelin Featured in Phase 2 Rare Ovarian Tumor Trial Update

On September 10, 2026, an update was recorded for a clinical trial involving triptorelin. The study, registered as NCT04931342 and titled "A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors," is a Phase 2 trial. Its current status is listed as active but not recruiting. This designation indicates that the study is ongoing and that participants are still being followed or treated, but new participants are not currently being enrolled. The trial evaluates biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors. No results, efficacy data, or safety findings have been reported as part of this status update. This brief reflects only the trial's registration status and phase as of the update date, and does not represent a report of clinical outcomes. Further details on the study design, eligibility criteria, and any future results can be found through the official trial registry listing. For more background on triptorelin, including its approved uses and general profile, readers can consult the compound overview.